Information

This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Confirm

Key Opinions in Medicine

  • Register
  • Login
Skip to content
  • Issues
    • Allergy & Immunology
    • Cardiology
    • Conference
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes & Endocrinology
    • Gastroenterology
    • General Medicine
    • Haematology
    • Hepatology
    • Infectious Diseases
    • Metabolic Disorders
    • Neurology
    • Nursing
    • Obstetrics & Gynaecology
    • Oncology
    • Paediatrics
    • Psychiatry
    • Rheumatology
    • Surgery Insights
    • Urology
  • Register
  • Login

download

Ixazomib▼: a novel oral proteasome inhibitor

Ixazomib▼: a novel oral proteasome inhibitor

...

Ixazomib▼: a novel oral proteasome inhibitor

Ixazomib▼: a novel oral proteasome inhibitor

...

Ixazomib▼: a novel oral proteasome inhibitor

Ixazomib▼: a novel oral proteasome inhibitor

...

Ixazomib▼: a novel oral proteasome inhibitor

Ixazomib▼: a novel oral proteasome inhibitor

...

IL-17A-Inhibitor bei Plaque-Psoriasis

IL-17A-Inhibitor bei Plaque-Psoriasis

...

IL-17A-Inhibitor bei Plaque-Psoriasis

IL-17A-Inhibitor bei Plaque-Psoriasis

...

IL-17A-Inhibitor bei Plaque-Psoriasis

IL-17A-Inhibitor bei Plaque-Psoriasis

...

IL-17A-Inhibitor bei Plaque-Psoriasis

IL-17A-Inhibitor bei Plaque-Psoriasis

...

IL-17A-Inhibitor bei Plaque-Psoriasis

IL-17A-Inhibitor bei Plaque-Psoriasis

...

IL-17A-Inhibitor bei Plaque-Psoriasis

IL-17A-Inhibitor bei Plaque-Psoriasis

...

1 … 18 19 20 21 22 … 38

Search Issues

RSS Feeds

  • All issues

Popular Issues

Konkurrenz für den Therapiestandard

MOVICOL® (PEG3350 plus electrolytes): 20 years of evidence-based use

Copyright © 2000-2026 by John Wiley & Sons, Inc., or related companies. All rights reserved.
Review our privacy policy. Cookie Preferences.
Web design and marketing agency Leamington Spa